Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hypofractionated IMRT + Carboplatin + Paclitaxel for Inoperable Esophageal Cancer
NCT04046575Phase 1Active, not recruiting
- Sponsor
- Washington University School of Medicine
- Start
- Nov 2019
- Primary completion
- Jun 2025
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of carboplatin and Paclitaxel Micelles for Injection in esophageal cancer, sponsored by Washington University School of Medicine. Primary endpoint: Maximum tolerated dose of hypofractionated IMRT with chemotherapy at 6 months. Started Nov 2019; status: active, not recruiting.
02
Drugs
carboplatinPaclitaxel Micelles for Injection
03
Conditions
esophageal cancer
Beyond the preview
Go deeper on NCT04046575.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04046575.